Lower versus standard sucrose dose for treating hypoglycemia in patients with type 1 diabetes mellitus in therapy with predictive low glucose suspend (PLGS) augmented insulin pumps: A randomized crossover trial in Santiago, Chile

Simple item page
dc.catalogadorjwg
dc.contributor.authorGrassi Corrales, Bruno
dc.contributor.authorOnetto Flores, María Teresa
dc.contributor.authorZapata Olivares, Yazmin Alejandra
dc.contributor.authorJofre Mendoza, Paulina Eugenia
dc.contributor.authorEcheverria Errazuriz, Guadalupe
dc.date.accessioned2024-05-30T15:30:58Z
dc.date.available2024-05-30T15:30:58Z
dc.date.issued2021
dc.description.abstractBackground and aims: Recommended hypoglycemia treatment in adults with T1D consists of 15 g of rapid absorption carbohydrates. We aimed to evaluate the response to fewer carbohydrates for treating hypoglycemia in patients with T1D on insulin pumps with predictive suspension technology (PLGS).
dc.description.abstractMethods: T1D patients on insulin pumps with PLGS were randomized to receive 10 or 15 g of sucrose per hypoglycemia for two weeks (S10 and S15 groups, respectively) when capillary blood glucose (BG) was <70 mg/dL, with crossover after two weeks. Evolution of capillary BG, active insulin, and suspension time were assessed.
dc.description.abstractResults: 59 hypoglycemic episodes were analyzed, 33 in S10 and 26 in S15. Baseline BG in S10 was 54.3 +/- 7.7 mg/dL versus 56.9 +/- 8.8 in S15 (p = 0,239). Active insulin, present in 85% of the episodes, and PLGS suspension time were similar between groups. BG at 15 min was 77 mg/dL in S10 and 95 mg/dL in S15 (p = 0.0007). In S10, 21% of the episodes required to repeat the treatment after 15 min compared with none on S15, with a RR of 0,79 (95% CI 0.66, 0.940, p = 0,014) for successfully treating the episode. Sensor glucose was significantly different from BG at the moment of the hypoglycemia and control 15 min after treatment. No severe hypoglycemia and no rebound hyperglycemia occurred in neither group.
dc.description.abstractConclusions: A hypoglycemia treatment protocol with a lower dose of sucrose might be insufficient despite PLGS technology. Our data suggest that standard doses of sucrose should still be recommended. (C) 2021 Diabetes India. Published by Elsevier Ltd. All rights reserved.
dc.format.extent7 páginas
dc.fuente.origenWOS
dc.identifier.doi10.1016/j.dsx.2021.03.017
dc.identifier.eissn1878-0334
dc.identifier.issn1871-4021
dc.identifier.pubmedidMEDLINE:33813244
dc.identifier.urihttps://doi.org/10.1016/j.dsx.2021.03.017
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/85988
dc.identifier.wosidWOS:000661873400009
dc.information.autorucEscuela de Medicina; Grassi Corrales Bruno; 0000-0003-0095-9740; 132804
dc.information.autorucEscuela de Medicina; Onetto Flores Maria Teresa; S/I; 1124999
dc.information.autorucEscuela de Medicina; Zapata Olivares Yazmin Alejandra; S/I; 250507
dc.information.autorucEscuela de Medicina; Jofre Mendoza Paulina Eugenia; S/I; 1023810
dc.information.autorucEscuela de Medicina; Echeverria Errazuriz Guadalupe; 0000-0002-2915-0171; 9504
dc.issue.numero3
dc.language.isoen
dc.nota.accesocontenido parcial
dc.pagina.final701
dc.pagina.inicio695
dc.publisherELSEVIER SCI LTD
dc.revistaDIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS
dc.rightsacceso restringido
dc.subjectType 1 diabetes
dc.subjectHypoglycemia
dc.subjectInsulin pumps
dc.subjectContinuous glucose monitoring
dc.subjectDiabetes education
dc.subject.ddc610
dc.subject.deweyMedicina y saludes_ES
dc.titleLower versus standard sucrose dose for treating hypoglycemia in patients with type 1 diabetes mellitus in therapy with predictive low glucose suspend (PLGS) augmented insulin pumps: A randomized crossover trial in Santiago, Chile
dc.typeartículo
dc.volumen15
sipa.codpersvinculados132804
sipa.codpersvinculados1124999
sipa.codpersvinculados250507
sipa.codpersvinculados1023810
sipa.codpersvinculados9504
sipa.trazabilidadORCID;2024-05-27
Files
Collections
Artículos de revistas